Cancer-induced systemic myeloid dysfunction: implications for treatment and a novel nanoparticle approach for its correction

Unlike other regulatory circuits, cancer-induced myeloid dysfunction involves more than an accumulation of impaired dendritic cells (DCs), protumoral macrophages and myeloid derived suppressor cells (MDSCs) in the tumor microenvironment (TME). It is also characterized by “aberrant” myelopoiesis that results in the accumulation and expansion of immature myeloid precursors with a suppressive phenotype in the systemic circulation. The first part of this review briefly describes the evidence for and consequences of this systemic dysfunctional myelopoiesis and the po ssible reinforcement of this phenomenon by conventional treatments used in patients with cancer, in particular chemotherapy and G-CSF.
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Source Type: research